1	Connecting the Dots: Systematic Exploration of COVID-19 and
2	Acute Kidney Injury through Meta-Analysis
3	Md. Safiullah Sarker <sup>1</sup> , Rubiyat Jahan <sup>2*</sup>
4	<sup>1</sup> Virology Laboratory, International Centre for Diarrhoeal Disease Research, Bangladesh
5	(icddr,b), Dhaka 1212, Bangladesh. <sup>2</sup> School of Business and Economics, North South University,
6	Dhaka 1229, Bangladesh
7	*Corresponding author: School of Business and Economics, North South University, Dhaka
8	1229, Bangladesh, Phone: +8801302847151, Email: rubiyat.sarker@northsouth.edu
9	Abstract
10	Objective
11	COVID-19 pandemic is a danger for the whole world. Also, our knowledge about acute kidney
12	injury (AKI) in COVID-19 patients is incomplete. Few studies informed that the problem of
13	AKI is a common complication, but other studies concluded that AKI is only an unusual event
14	during COVID-19 infection. This study using meta-analysis tools aimed to find disease
15	progression and mortality risk in affected population.
16	Methods
17	We systematically reviewed the literature on COVID-19 and its association with AKI as per
18	PRISMA guideline. All authors independently performed a literature search until 8th June 2023.
19	We included studies which reported clinical characteristics, incidence of AKI, and the death risk
20	with AKI during COVID-19 infection.
21	Findings
22	We have included five studies and all of them reported older age (73-75) and males (67-84.2%)

were risk factors for patient illness. COVID-19 patients with AKI had more than five times

mortality risk of those without AKI. Diagnosis time after disease onset was 8.5 days (IQR, [4– 24 11]). Fatality time after initial hospital admission was 13.5 days (IQR, 8–17). In non-survivors, 25 26 systemic inflammation with high temperature, abnormal respiratory rate, acute myocardial injury, and acute respiratory distress syndrome (ARDS) were observed. Abnormal biochemical 27 28 analytes and immunological markers were observed. 29 Conclusion Our analyses indicate that patients experienced repeated changes in biochemical analytes and 30 31 immune marker with the progression of the disease. It indicates the requirement of early 32 management and treatment. Further study is required to conclude and to have better knowledge of AKI mechanism with COVID-19 infection. 33 Keywords: Acute kidney injury, COVID-19, Coronavirus, mortality, SARS-CoV-2, non-34 survivor, in-hospital death. 35 Introduction 36 As per worldometer report as of 8<sup>th</sup> June, 2023 there were 690,140,273 Coronavirus positive 37 cases and 6,896,133 people were died [1]. The Coronavirus 2019 (COVID-19) disease outbreak 38 occurred in Wuhan, Hubei Province, China, in December 2019, and rapidly spread to other areas 39 40 of the worldwide. Now, it is well known that the novel Coronavirus is more dangerous than a common respiratory virus. Usually it targets the lungs, but it can attack the whole body. 41 42 Physician observed that it can cause blood clot and multi organ failure. It was observed that a 43 certain portion of COVID-19 affected patient develops acute kidney injury with normal 44 creatinine level [6]. The SARS-CoV-2 virus affect the respiratory organ but based on clinical findings of several 45 46 deceased cases the involvement of other organs needs to be explored [6]. Since information on

47 kidney disease in patients with COVID-19 is limited, in this meta-analysis we want to determine

- 48 the incidence of acute kidney injury (AKI) in patients with COVID-19 by pooling the available
- 49 published data. Further, we evaluated the association between markers of abnormal kidney
- 50 function and death in patients with COVID-19. Now, there are still no specific treatments or
- vaccines for COVID-19 affected patient. We want to discuss possible pathogenic mechanism
- 52 which may shed light on future intervention.

# 53 Material and methods

54 We systematically reviewed the literature on COVID-19 and its association with acute kidney

55 injury symptoms. The systematic review was performed according to the Preferred Reporting

56 Items for Systematic Reviews and Meta-Analyses (PRISMA) statement (Table 1)[2].

57 **Table 1.** Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA)

58 checklist.

Section/topic	#	Checklist item	Reported in main text on				
TITLE							
Title	Injury through Meta-Analysis						
ABSTRACT							
Structured summary	<i>J G</i> , <i>H</i>		p. 1-2				
INTRODUCTION							
Rationale	3	Rationale for the review in the context of what is already known.	p. 1-2				
Objectives	A statement of questions are addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).						
METHODS	•						
Protocol and registration	5	Review protocol	None				
Eligibility criteria	6	Study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status)	p. 3				
Information sources	7	All information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies).	p. 3				
Search	8	Electronic search strategy.	Table 2				
Study selection	dy selection 9 Studies selected (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).		p. 4				
Data collection process	10	Method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	p. 4				

Data items	11	List of all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	p. 4			
Risk of bias in individual studies						
Summary measures	13	Principal summary measures (e.g., risk ratio, difference in means).	p. 4			
Synthesis of results	14	Methods of handling data and combining results of studies, including measures of consistency (e.g., I <sup>2</sup> ) for each meta-analysis.	p. 5			
Risk of bias across studies	ias across 15 Assessment of risk of bias.					
Additional analyses	16	Methods of additional analyses	None			
RESULTS						
Study selection	17	Numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	p.4, Figure 1			
Study characteristics	18	Characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and the citations.	Table 3, 4			
Risk of bias within studies	19	Data on risk of bias of each study and outcome level assessment.	Figure 3,Table 7			
Results of individual studies	20	Outcomes considered (benefits or harms) : (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, with a forest plot.	Table 5,6 Figure 2a,2b			
Synthesis of results	21	Results of meta-analysis done, including confidence intervals and measures of consistency.	p. 4-5 Figure 2a,2b			
Risk of bias across studies	22	Results of risk of bias across studies.	Figure 3 Table 7			
Additional analysis	23	Results of additional analyses.	None			
DISCUSSION	•					
Summary of evidence	24	Main findings including the strength of evidence for each main outcome.	p. 13			
Limitations	25	Limitations at study and outcome level.	p. 16			
Conclusions						
FUNDING						
Funding	27	Sources of funding for the systematic review and other support.	р. 17			

59

60 Two authors independently performed a literature search using PubMed, Web of Science,

Embase, and Cochrane Library fulfilled the pre-specified criteria until 8th June, 2023 to include

62 studies reported the necessary clinic characteristics, the incidence of AKI, the mortality with

63 AKI and the death risk with AKI during COVID-19 infection were pooled for statistical analysis

64 by MedCalc software [3] to get conclusions.

65 Literature search

66	A comprehensive literature search was performed using combination of keywords (MeSH terms
67	and free text words) including 'COVID-19'/ 'SARS-CoV-2', 'AKI'/'acute kidney injury', and
68	"English language". PubMed, Embase, Cochrane library, Cochrane COVID-19 Study Register
69	and DIRECTORY OF OPEN ACCESS JOURNALS(DOAJ) and Web of Science were searched
70	up to 8th June 2023. The search strategy was present in Table 2. Additional articles were sought
71	from the reference lists of the included studies.
72	
73	
74	
75	
76	
77	
78	
79	
80	
81	
82	
83	
84	
85	
86	
87	
88	
89	
90	

- 91 Table 2. Search criteria for systematically reviewing COVID-19 and Acute kidney injury (AKI) in
- 92 PubMed, Embase Cochrane Library, Cochrane COVID-19 Study Register and Web of Science

ID	Search site	Key word	Search terms	Hits
#1	PubMed	17,850		
#2	PubMed	(COVID-19) AND (Acute Kidney Injury)	((((((("covid 19"[All Fields] OR "covid 2019"[All Fields]) OR "severe acute respiratory syndrome coronavirus 2"[Supplementary Concept]) OR "severe acute respiratory syndrome coronavirus 2"[All Fields]) OR "2019 ncov"[All Fields]) OR "sars cov 2"[All Fields]) OR "2019ncov"[All Fields]) OR (("wuhan"[All Fields] AND ("coronavirus"[MeSH Terms] OR "coronavirus"[All Fields])) AND (2019/12/1:2023/05/31[Date - Publication] OR 2020/1/1:2023/05/31[Date - Publication]))) AND (("acute kidney injury"[MeSH Terms] OR (("acute"[All Fields] AND "kidney"[All Fields]) AND "injury"[All Fields])) OR "acute kidney injury"[All Fields])	78
#3	PubMed	Acute Kidney Injury) AND (SERS-CoV- 2)	("acute kidney injury"[MeSH Terms] OR (("acute"[All Fields] AND "kidney"[All Fields]) AND "injury"[All Fields])) OR "acute kidney injury"[All Fields]	62063
#4	PubMed	((Acute Kidney Injury) AND (SERS- CoV-2)) OR (COVID-19)	(("acute kidney injury"[MeSH Terms] OR (("acute"[All Fields] AND "kidney"[All Fields]) AND "injury"[All Fields])) OR "acute kidney injury"[All Fields]) OR ((((((("covid 19"[All Fields] OR "covid 2019"[All Fields]) OR "severe acute respiratory syndrome coronavirus 2"[Supplementary Concept]) OR "severe acute respiratory syndrome coronavirus 2"[All Fields]) OR "2019 ncov"[All Fields]) OR "sars cov 2"[All Fields]) OR "2019ncov"[All Fields]) OR "sars cov 2"[All Fields]) OR "2019ncov"[All Fields]) OR (("wuhan"[All Fields] AND ("coronavirus"[MeSH Terms] OR "coronavirus"[All Fields])) AND (2019/12/1:2023/05/31[Date - Publication] OR 2020/1/1:2023/05/31[Date - Publication])))	79835
#5	PubMed	Acute Kidney Injury	("acute kidney injury"[MeSH Terms] OR (("acute"[All Fields] AND "kidney"[All Fields]) AND "injury"[All Fields])) OR "acute kidney injury"[All Fields]	62063
#6	PubMed	SERS-CoV-2	it retrieved zero results.	0
#7	PubMed	AKI	("AKI"[All Fields]	13853
#8	PubMed	(Coronavirus disease 2019) AND (acute kidney injury)	(("covid 19"[Supplementary Concept] OR "covid 19"[All Fields]) OR "coronavirus disease 2019"[All Fields]) AND (("acute kidney injury"[MeSH Terms] OR (("acute"[All Fields] AND "kidney"[All Fields]) AND "injury"[All Fields])) OR "acute kidney injury"[All Fields])	85

#9	PubMed	((Coronavirus disease 2019) AND (acute kidney injury)) AND (English[Lang uage])	((("covid 19"[Supplementary Concept] OR "covid 19"[All Fields]) OR "coronavirus disease 2019"[All Fields]) AND (("acute kidney injury"[MeSH Terms] OR (("acute"[All Fields] AND "kidney"[All Fields]) AND "injury"[All Fields])) OR "acute kidney injury"[All Fields])) AND "English"[Language]	81
#10	PubMed	((COVID-19) AND (acute kidney injury)) AND (English[Lang uage])	((((((("covid 19"[All Fields] OR "covid 2019"[All Fields]) OR "severe acute respiratory syndrome coronavirus 2"[Supplementary Concept]) OR "severe acute respiratory syndrome coronavirus 2"[All Fields]) OR "2019 ncov"[All Fields]) OR "sars cov 2"[All Fields]) OR "2019ncov"[All Fields]) OR (("wuhan"[All Fields] AND ("coronavirus"[MeSH Terms] OR "coronavirus"[All Fields])) AND (2019/12/1:2023/05/31[Date - Publication] OR 2020/1/1:2023/05/31[Date - Publication])) AND (("acute kidney injury"[MeSH Terms] OR (("acute"[All Fields] AND "kidney"[All Fields]) AND "injury"[All Fields])) OR "acute kidney injury"[All Fields])) AND "English"[Language]	82
#11	PubMed	((novel coronavirus disease) AND (acute kidney injury)) AND (English[Lang uage])	(((("novel"[All Fields] OR "novel s"[All Fields]) OR "novels"[All Fields]) AND (("coronavirus"[MeSH Terms] OR "coronavirus"[All Fields]) OR "coronaviruses"[All Fields]) AND (((("disease"[MeSH Terms] OR "disease"[All Fields]) OR "diseases"[All Fields]) OR "disease s"[All Fields]) OR "diseased"[All Fields])) OR "disease s"[All Fields]) OR "diseased"[All Fields])) AND (("acute kidney injury"[MeSH Terms] OR (("acute"[All Fields] AND "kidney"[All Fields]) AND "injury"[All Fields])) OR "acute kidney injury"[All Fields])) AND "English"[Language]	24
#12	PubMed	(((COVID-19) AND (acute kidney injury)) AND (English[Lang uage])) OR (((novel coronavirus disease) AND (acute kidney injury)) AND (English[Lang uage]))	(((((((("covid 19"[All Fields] OR "covid 2019"[All Fields]) OR "severe acute respiratory syndrome coronavirus 2"[Supplementary Concept]) OR "severe acute respiratory syndrome coronavirus 2"[All Fields]) OR "2019 ncov"[All Fields]) OR "sars cov 2"[All Fields]) OR "2019ncov"[All	88

#13	PubMed	AND (English[Lang uage])) OR (((novel coronavirus disease) AND (acute kidney injury)) AND (English[Lang uage]))	syndrome coronavirus 2"[All Fields]) OR "2019 ncov"[All Fields]) OR "sars cov 2"[All Fields]) OR "2019ncov"[All Fields]) OR (("wuhan"[All Fields] AND ("coronavirus"[MeSH Terms] OR "coronavirus"[All Fields])) AND (2019/12/1:2023/5/31[Date - Publication] OR 2020/1/1:2023/05/31[Date - Publication]))) AND (("acute kidney injury"[MeSH Terms] OR (("acute"[All Fields] AND "kidney"[All Fields]) AND "injury"[All Fields])) OR "acute kidney injury"[All Fields])) AND "English"[Language]) OR ((((("novel"[All Fields]) OR "novel s"[All Fields]) OR "novels"[All Fields]) AND (("coronavirus"[MeSH Terms] OR "coronavirus"[All Fields]) OR "coronaviruses"[All Fields]) AND (((("disease"[MeSH Terms] OR "disease"[All Fields]) OR "diseases"[All Fields]) OR "disease s"[All Fields]) OR "diseases"[All Fields]) OR "disease s"[All Fields]) OR "diseased"[All Fields])) AND (("acute kidney injury"[MeSH Terms] OR (("acute"[All Fields] AND "kidney"[All Fields]) AND (("acute"[All Fields])) OR "acute kidney injury"[MeSH Terms] OR (("acute"[All Fields] AND "kidney"[All Fields]) AND "injury"[All Fields])) OR "acute kidney injury"[MeSH Terms] OR (("acute"[All Fields])) OR "acute kidney injury"[MeSH Terms] OR (("acute"[All Fields])) OR "acute kidney injury"[MeSH Terms] OR (("acute"[All Fields])) OR "acute kidney injury"[MeSH	84
#14	Library	AND AKI		5
#15	Cochrane Library	COVID-19 AND Acute Kidney Injury	(COVID-19 AND Acute Kidney Injury):ti,ab,kw (Word variations have been searched)	6
#16	Cochrane COVID- 19 Study Register	COVID-19 and acute kidney injury	COVID-19 and acute kidney injury	1,711
#17	DIRECT ORY OF OPEN ACCESS JOURNA LS(DOAJ )	COVID-19 and acute kidney injury	COVID-19 and acute kidney injury	13
#20	Embase	COVID-19 AND acute kidney injury	"COVID-19 AND acute kidney injury" in journals	2,360
#21	Web of Science	COVID-19 AND acute kidney injury	(from Web of Science Core Collection)	24

93

# 94 Selection criteria

All articles identified from the literature search were screened by two independent reviewers

96 (M.S.S and R.J). We included studies on COVID-19 in adult patients. Full articles, Conferences

97	abstracts, Case reports, case series, non-randomized studies, randomized trials and observational
98	studies, that were published in English were included in this review. Commentaries, letters to
99	editors and editorials were also included. Studies on severe acute respiratory syndrome (SARS)
100	and Middles East respiratory syndrome (MERS) but not COVID-19 were excluded.
101	Data Collection
102	For eligible studies, study information including first authors, site of study, inclusion and
103	exclusion criteria, sample size, age and sex were recorded. A standardized form for data entry
104	has been devised to focus on the following areas: number of patients, number of AKI patients,
105	AKI related indicators (according to Acute Kidney Injury Network (AKIN): (a) an increase
106	in the serum creatinine level to $\geq 0.3$ mg/dL, (b) an increase in baseline serum creatinine level to
107	$\geq$ 150%)[4], AKI related death (Table 3 and 4).
108	
109	
110	
111	
112	
113	
114	
115	
116	
117	
118	
119	

121	Table 3. Characteristics of studies included in the systematic review (qualitative analysis).	

SL#	Study name	Reference#	Journal	Date of Publication	Study Population (n)	Age in Years (range)	Sex		
							M, n (%)	F, n (%)	
1	Lim et al.,	4	J. Clin. Med	3 June 2020	160	69.0 (24.0-98.0)	88 (55)	72 (55)	
2	Shao et al.,	5	Front. Med	22 May 2020	155	48.0 (7.0–96.0)	62(40)	93(60)	
3	Cheng et al.,	6	Kidney International	16 March 2020	701	63.0 (50.0–71.0)	367(52.4)	334(47.7)	
4	Wang et al	7	Critical Care	30 April 2020	107	51.0 (19.0–92.0)	57 (53.3)	44(46.7)	

Reference	Authors	Journal	Date of Publicat ion	Study popul ation	AKI definition	AKI related death	AKI	Baseline creatinine	Blood Urea Nitrogen (BUN)	Proteinuria	Hematuria	eGF R	D-dimer	RRT(n)
4	Lim et al.,	J. Clin. Med	3 June 2020	164	AKIN	17	30	30/30	30/160	N/A	N/A	30/3 0	16/30	CRRT (5)
5	Shao et al.,	Front. Med	22 May 2020	155	N/A	7	7	18/155	18/155	N/A	N/A	N/A	18/155	CRRT (7)
6	Cheng et al.,	Kidney International	16 March 2020	701	KDIGO	HR	36	36/36	701	194/442	118/442	701/ 701	512/661	N/A
7	Wang et al	Critical Care	30 April 2020	107	KDIGO	OR	14	107	N/A	N/A	N/A	N/A	107	CRRT (4)
8	Li et al.	The Lancet Infectious Diseases	2020	193	KDIGO	HR	55	43/193	59/193	88/147	71/147	N/A	128/182	CRRT (7)

# 133 Table 4: Characteristics of studies included in the systematic review (Quantitative analysis)

134

Abbreviations: AKI, acute kidney injury; AKIN, Acute Kidney Injury Network; RRT, Renal Replacement Therapy, (n) indicate number of

136 patients received RRT, CRRT, continuous renal replacement therapy; KDIGO, Kidney Disease: Improving Global Outcomes; HR, Hazard Ratio,

137 OR, Odd Ratio,

# 140 Data synthesis and statistical analysis

141 Primary outcomes of our study included acute kidney injury (AKI) in COVID-19 infected patient (Table 5),

142

139

Table 5. Incidence of AKI patient those who were SARS-CoV-2 positive

SL	Study name	Ref#	AKI(n)	Total	Non-	Death in	Total	Prevalence (%)	Weight (%)	Risk
#				Death	AKI(n)	non-				Ratio
				(n)		AKI (n)				
1	Lim et al.,2020	4	17	30	134	13	164	10.37	12.42	6.6
2	Shao et al.,2020	5	7	18	137	11	155	4.52	11.74	5.1
3	Cheng et al., 2020	6	36	113	588	77	701	13.08	8.11	15.0
4	Wang et al, 2020	7	14	19	88	5	107	5.14	53.11	2.6
5	Li et al.,2020	8	32	55	138	23	170	28.50	14.62	4.3
	Total		106	235	1085	129	1320	8	100	4.1

143

144 death of AKI developed patients (Table 6),

145


Table 6. Death in acute kidney injury patient who were SARS-COV-2 infected


#	Study name	Ref#	Death (n)	AKI(n)	Prevalence (%)	Weight (%)
1	Lim et al.,	4	17	30	56.67	18.99
2	Liang et al.,	5	7	18	38.89	11.39
3	Cheng et al.,	6	6	36	16.67	22.78
4	Wang et al.,	7	14	19	73.68	12.03
5	Li et al.	8	32	55	58.18	34.81

146

clinical symptoms, markers of kidney injury. For the AKI prevalence rates, data were pool

#### 148






173	illustrating the prevalence, 95% confidence intervals and weightings. Cochran's Q test was used
174	to detect heterogeneity, and a $p$ value of $< 0.10$ indicates significant heterogeneity. <sup>12</sup> statistics
175	was calculated to measure the proportion of total variation in study estimates attributed to
176	heterogeneity with $I^2 > 50\%$ suggests substantial heterogeneity.
177	Results
178	The PRISMA flow diagram was shown in Figure 1. A total of 1723 records were identified upon
179	literature search, and 11 additional records were sought from reference lists of the included
180	literature. 1535 records remained after removing duplicates. Among them, 757 were screened
181	and 816 were excluded (641 not related and 135 review articles). Of the screened articles 108
182	were assessed for eligibility (COVID-19 and AKI) and 649 were excluded as not related to AKI.
183	Of the 108 articles only 5 were eligible for serum creatinine marker. These five articles were
184	selected for quantitative analysis [4-8]. Using funnel plot one study was excluded and the
185	remaining four were selected for qualitative analysis. Table 3 give a clear picture of basic
186	characteristics of the 4 studies [4,6-8] that were included in the qualitative analysis. The
187	Newcastle-Ottawa score of the included studies is shown in Table 7.

188 Table 7. Results of quality assessment for risk of selection bias as per Newcastle-Ottawa Scale

Author, year	Age	Gender	Sampling	Location	Author,	Total	Risk of selection
			method		year	scores	bias
Lim, JH,2020	1	1	1	1	1	5	Low risk
Liang Shao,2020	1	1	1	1	1	5	Low risk
Cheng Y,2020	1	1	1	1	1	5	Low risk
Wang et al,2020	1	1	1	1	1	5	Low risk



194 Publication bias was shown in the funnel plot analysis in Figure 3.

We have included five studies for our analysis. Of these five all of them reported older age andmale sex were risk factors for patient illness. We were able to extract data from three studies.

219	The study by Lim et al., reported of the non-survivor median age was 75.0 years and about 67%
220	were male [4]. Shao et al., observed that of the non-survivors, the median age was 73.5 years,
221	and the proportion of males was 72.2% [5]. Wang et al., also reported the same findings [of the
222	non-survivors(n=19) were of 73.0 years and 84.2% (16/19) were male] [7].
223	
224	In-hospital mortality was higher in AKI patients:
225	All of the studies observed most case fatality in AKI patient specially in stage III AKI group who
226	needed renal replacement therapy. Study of Li et al. reported by Cox regression analysis that
227	COVID-19 patients who developed AKI had a ~5.3-times mortality risk of those without AKI
228	[8].
229	
230	The interval between disease onset and Diagnosis:
231	The incubation period of COVID-19 is considered to be up to14 days following exposure [10-
232	12]. Two studies highlighted on this issue. Cheng et al and Wang et al., define the date of disease
233	onset was the day when the first symptom was noticed [7]. Wang et al also informed that
234	
	"median duration from illness onset to admission was 10 days". Shao et al.; observed that
235	"median duration from illness onset to admission was 10 days". Shao et al.; observed that 'diagnosis time after disease onset was 8.5 days (IQR, [4–11]) [5]. Lim et al. reported that there
235 236	
	'diagnosis time after disease onset was 8.5 days (IQR, [4–11]) [5]. Lim et al. reported that there
236	'diagnosis time after disease onset was 8.5 days (IQR, [4–11]) [5]. Lim et al. reported that there were 17 deaths among AKI patients; [stage-I: 4 (28.6%), stageII: 1 (25.0%), and stageIII: 12
236 237	'diagnosis time after disease onset was 8.5 days (IQR, [4–11]) [5]. Lim et al. reported that there were 17 deaths among AKI patients; [stage-I: 4 (28.6%), stageII: 1 (25.0%), and stageIII: 12 (100.0%), respectively] [4]. It was also mentioned in the same article that in-hospital mortality

241	(95% CI = 2.43–100.64), $p = 0.004$ ). Using Kaplan–Meier analysis Cheng et.al, showed that
242	patients with kidney disease had a significantly higher risk for in-hospital death. Cox
243	proportional hazard regression established that AKI stage 1(hazard ratio: 1.90, 95% confidence
244	interval: 0.76-4.76), stage 2 (3.51, 1.49-8.26), stage 3 (4.38, 2.31-8.31) [6].
245	Fatality time:
246	Two studies reported about the fatality time form onset of illness to death. Shao et al observed a
247	"period of 7–13 days after illness onset is the critical stage in the COVID-19 course. All patients
248	died within 45 days after the initial hospital admission with a median survivor time of 13.5 days
249	(IQR, 8–17)" [5]. Cheng et al., also support similar findings and observed that the prevalence of
250	kidney disease on admission and the development of AKI during hospitalization in patients with
251	COVID-19 is high and is associated with in-hospital mortality [6].
252	
253	Inflammation in AKI and acute respiratory distress syndrome
254	Wang et al; observed in non-survivors, the appearance of systemic inflammation with high
255	temperature, abnormal respiratory rate, WBC counts and neutrophil counts. Subsequently,
256	multiple organ dysfunction syndromes (MODS) occurred with thrombocytopenia, renal failure,
257	acute myocardial injury, and ARDS [7].
258	
259	Biochemical parameters:
260	The following abnormal biochemical parameter were observed in COVID-19 patient with AKI:
260 261	
	The following abnormal biochemical parameter were observed in COVID-19 patient with AKI:
261	The following abnormal biochemical parameter were observed in COVID-19 patient with AKI: Elevated baseline serum creatinine:

264	110 micromoles per liter (µmol/L) (0.7 to 1.2 milligrams per deciliter (mg/dL)) for men and 45
265	to 90 $\mu$ mol/L (0.5 to 1.0 mg/dL) for women [13]. Four studies observed elevated serum
266	creatinine in AKI patient [5-8]. Shao et al., observed an elevated serum creatinine level at day of
267	admission and day of death. [88.25 µmol/L (76.70–123.70) and 123.60 (70.80–328.70)
268	respectively, median and IQR]. Cheng Y also observed nearly fifteen percent of the patient on
269	admission had elevated serum creatinine (77 $\pm$ 31, mean $\pm$ SD). In this study cox proportional
270	hazard regression confirmed that elevated baseline serum creatinine (hazard ratio: 2.10, 95%
271	confidence interval: 1.36-3.26) was independent risk factor for in-hospital death. Wang et al.,
272	and Li et al., also observed the same situation.
273	
274	Elevated baseline blood urea nitrogen
275	Blood urea nitrogen (BUN) normal reference range for adults is 3.6-7.1 mmol/L[14]. Cheng et
276	al., observed 13.1% patient has elevated BUN during admission and the whole course of
277	treatment. Cox proportional hazard regression confirmed that elevated baseline blood urea
278	nitrogen (hazard ratio: 3.97, 95% confidence interval: 2.57-6.14), AKI stage 1 (1.90, 0.76-4.76),
279	stage 2 (3.51, 1.49-8.26), stage 3 (4.38, 2.31-8.31) was independent risk factor for in-hospital
280	death. Wang et al., and Li et al., also observed the same situation. Wang et al., observed
281	admission values of blood urea nitrogen were elevated in the non-survivors. Li et al., observed
282	"On hospital admission, a remarkable fraction of patients had signs of kidney dysfunctions,
283	including 14% with increased levels of blood urea nitrogen" [8].
284	Estimated Glomerular Filtration Rate (eGFR)
285	A normal eGFR for adults is greater than 90 mL/min/1.73m2, according to the National Kidney
286	Foundation and actual numbers are only reported once values are less than 60 mL/min/1.73m <sup>2</sup> .[

15] The study by Cheng et al., reported during admission 13.1% patients had reduced eGFR (<</li>
60 ml/min/1.73m<sup>2</sup>).

289

#### 290 High level of D-dimer

- 291 D-dimer is a protein fragments formed when a blood clot gets dissolved in blood stream. Acute
- kidney injury (AKI) affects the hypercoagulable state [16] of the body. As coagulation
- biomarkers D-dimer is measured. It's normal value is 0–500 mg/L and Shao et al., observed an
- extremely high level of D-dimer on the death date compared with the admission date (median,
- 295 3542.50 [IQR, 2797.00–10929.00] vs. 492.50 [IQR, 273.00–2139.00], p<0.05). Cheng et al.,
- observed an elevated D-dimer on 77.5 % COVID-19 patients during admission. Wang et al.,
- observed the non-survivors had higher D-dimer level (439 mg/L [202–1991]vs 191 mg/L [108–
- $298 \quad 327$ ], P = 0.003) in COVID-19 patients. Li et al., showed that using univariate cox regression
- analysis, D-dimer were significantly associated with the death of COVID-19 patient [5-8].

#### 300 **Proteinuria**

Patient with proteinuria have urine containing an unusual amount of protein. The condition is a 301 signal of kidney disease. During acute kidney injury albumin leak form the damage kidney filters 302 303 into the urine [17]. The normal mean albumin excretion rate (AER) is 5-10 mg/day, with an AER of >30 mg/day considered abnormal [18]. In this review we included five studies and two of them 304 305 highlighted on proteinuria in AKI patient. Cheng et al., observed that during hospital admission, 306 almost half of patients had proteinuria. One in twenty patient developed AKI during the study period. Kaplan–Meier analysis confirmed that patients with kidney disease had a top risk for in-307 308 hospital death. Cox proportional hazard regression support that proteinuria 1+ (hazard ratio: 309 1.80, 95% confidence interval: 0.81-4.00,  $2+\sim3+(4.84, 2.00-11.70)$ , had independent risk factors

for in-hospital death [6]. Study by Li et al., also observed during hospital admission, more than
half of patients had proteinuria. The univariate cox regression analysis confirms that proteinuria
was remarkably associated with the fatality of COVID-19 patients [8].

313

### 314 Hematuria

Hematuria is defined as the presence of 5 or more red blood cells (RBCs) per high-power field in 315 3 of 3 consecutive centrifuged specimens available at least 1 week apart. It can be either visible 316 or microscopic. It may also be either symptomatic or asymptomatic, either temporary or 317 318 constant, and either alone or coupled with proteinuria and other urinary problem [19]. Two of our analyzed studies informed on hematuria in AKI patient. Cheng et al., observed that almost 319 320 one in four patients had hematuria during hospital admission. During the study period, AKI 321 occurred in almost five percent patients. It was observed that the AKI patient had a top risk for in-hospital mortality by Kaplan–Meier analysis. Cox proportional hazard regression analysis 322 confirmed that hematuria 1+(hazard ratio: 2.99, 95% confidence interval: 1.39-6.42), 2+~3+ 323 (5.56,2.58-12.01) were independent risk factors for in-hospital death [6]". Study by Li et al., 324 also support such observation. They showed during hospital admission, nearly half of patients 325 326 had hematuria. The univariate cox regression analysis confirms that hematuria was remarkably 327 associated with the casualty of COVID-19 patients [8].

328

#### 329 Immune parameters

# 330 Hematological parameter

331 Shao et al., observed that "with the deterioration of disease, most patients experienced

332 consecutive changes in lymphopenia, leukocytosis, thrombocytopenia. Regarding the immune

dysregulation, patients exhibited significantly decreased T lymphocytes in the peripheral blood,

including CD3+T, CD3+CD4+Th, andCD3+CD8+Tc cells". Wang at el., reported "in severe

cases, leukocytosis, neutrophilia, and deteriorating multi-organ dysfunction were dominant" [5].

336 The role of cytokine is well known by scientific community in viral infection. None of our

337 included studies analyzed cytokine profile. We reviewed literature about cytokine in SARS-

- 338 CoV-2 infection which is discussed below:
- 339

#### 340 Cytokine Storm in SARS-CoV-2 Infection

341 Abnormalities of the inflammatory cytokines profile are good trait during SARS-CoV infection.

342 They correlate with illness but poor prognostic marker [20-21]. Many studies observed a group of

patients with COVID-19 had inflammatory response and cytokine storm syndrome [22-24]. A

344 cytokine profile with hyper-inflammatory condition defined by a huge cytokine production and

serious problem with vital organs failure was observed in COVID-19 patients. In addition,

increased ferritin and IL-6 levels observed in more than hundred confirmed COVID-19 cases. It

indicates that virus related hyper-inflammation might be one leading cause of serious health

348 problem [25].

In a cohort of 53 patients with COVID-19 compared to healthy controls a marked increase of 14

pro- and anti-inflammatory cytokines were observed. Among them, interferon gamma induced

protein 10(IP-10), monocyte chemotactic protein-3(MCP-3) and interleukin (IL-1ra) were


significantly associated with disease severity [23]. It supports that abnormal inflammatory

353 cytokine release was dangerous for lung tissue injury and COVID-19 pathogenesis.

354

### 356 Possible Pathophysiology of AKI in COVID-19

- 357 The cause of kidney injury in COVID-19 is thought to be complex [43]. It is related to
- 358 cardiovascular comorbidity and influencing factors like nephrotoxin, bacteremia and
- 359 hypovolemia. The right ventricular failure due to COVID-19 pneumonia cause kidney
- 360 congestion following AKI. Also, left ventricular abnormalities generate low cardiac function,
- 361 arterial under filling, and kidney hypoperfusion. The endothelium of lung and kidney is disrupted
- 362 which cause proteinuria. Additionally, virus particles were present in renal endothelial cells as
- indicated by postmortem report. So, viremia is a possible cause of endothelial damage in the
- kidney and a probable contributor to AKI [44]. A schematic diagram is drawn in figure 4 to
- represent the possible pathophysiology of AKI in SARS-CoV-2 infection.



Acute kidney Injury in COVID-19

366

# 367 Figure-4: Mechanism of acute kidney injury in COVID-19 infection

- 368
- 369 Furthermore, SARS-CoV-2 can directly infect the renal tubular epithelium and podocytes
- through an angiotensin converting enzyme 2 (ACE2)-dependent pathway. It causes acute tubular
- 371 necrosis, mitochondrial abnormalities, the formation of protein reabsorption vacuoles, collapsing

glomerulopathy, and protein leakage in Bowman's capsule [45,46]. Another immunological 372 mechanism is also discussed nowadays in scientific community related to AKI. Reduced 373 374 lymphocyte count and elevated cytokine production is thought to be related to AKI [47,48]. Discussions 375 COVID-19, the disease caused by the novel coronavirus, affected 213 countries of the world. It 376 377 has infected nearly seven million people and almost half a million died. The coronavirus 2019 378 (COVID-19) disease outbreak occurred in Wuhan, Hubei Province, China, in December 2019, 379 and rapidly spread to other areas of the worldwide. Now, it is well known that the novel 380 coronavirus is dangerous than a simple respiratory virus. Usually it targets the lungs, but it can attack the whole body. Physician observed that it can cause blood clot and multi organ failure. It 381 was observed that a certain portion of COVID-19 affected patient develop acute kidney injury 382 with normal creatinine level. Thus, it bypasses the screening criteria and by this time the fatality 383 occurred[6]. 384 385 Our meta-analysis provided evidence that the incidence of AKI in hospitalized patients with COVID-19 infection is low, only about 8%. On the other hand, this AKI incidence during this 386

viral infection provides a strong danger signal: the in-hospital mortality in AKI with COVID-19
infected patients is bigger, which is up to 45%. Also the fatality risk with AKI in COVID-19
infected patients is extremely high. Based on our pooled calculation it is about 4 times higher
than those without AKI. Thus, clinicians should pay special attention to the treatment of COVID19 patients with severe AKI.

392

We have analysed five studies and all of them reported older age and male sex were risk factorsfor COVID-19. This finding is consistent with other studies. In a case series studies at Wuhan

Union Hospital, Beijing, China from January 29, 2020 to February 15, 2020 with COVID-19 395 infected 43 patients, observed older patients ( $\geq 65$  years old), were more likely to have a severe 396 397 type of COVID-19. Males develop more severe cases than females. In the comparable public data set of COVID-19, they also found that the percentage of older age ( $\geq 65$  years) was much 398 higher in the dead patients than who survived (83.8% in 37 deceased patients vs. 13.2% in 1,019 399 400 patients who survived) [26]. The number of men is about two and half times higher than that of women in the dead patients. Although men and women had the same vulnerability, male were 401 402 more prone to dying. Therefore, gender has a vital role in case fatality with COVID-19. This 403 gender factor, as well as higher incidences in men for most of the diseases could correlate with a general demographic fact of a shorter life expectancy in men compared to women in China and 404 in the world in general. Other studies from Beijing Municipal Medical Taskforce informed that 405 SARS-CoV-2 attack cells via the angiotensin-converting enzyme 2 (ACE2) receptor. It was 406 407 reported earlier that high protein expression of ACE2 receptor in specific organs correlated with 408 specific organ failures, indicated by corresponding clinical parameters in SARS patients [27, 28]. Also, it was reported earlier that circulating ACE2 levels are higher in men than in women [29]. 409 In-hospital mortality was higher in our analyzed AKI patients. Multiple organ dysfunction 410 411 including the liver, gastrointestinal tract and kidney have been reported in patients with COVID-19[24, 30]. One possible cause is that some of the COVID-19 patients had a history of chronic 412 413 kidney disease (CKD). Also, it was observed by some studies that the median time period 414 between the first symptoms and signs of COVID-19 and hospital admission was around a week 415 [8]. By this time the patients developed a pro-inflammatory condition with abnormalities in 416 cellular populations specially the immune cells [30]. Also, there is a higher risk for upper 417 respiratory tract infection [31] and pneumonia. [32]. Cheng et al., also explained that many

418 COVID-19 patients could not be admitted in the early stage of disease due to lack of hospital
419 beds. Earlier admission to hospital can help physician for management of the patient and disease
420 spread to prevent nosocomial infection [8].

421

422 There are several evidence that severe COVID-19 patients have high level of inflammatory

423 cytokines such as IL-1RA, IL-7, IL-8, IL-9, IL-10 [33,20]. These cytokines may contribute to

424 develop AKI in COVID19 patients. These cytokines interact with kidney cells and trigger

endothelial and tubular abnormalities. It was reported that  $TNF-\alpha$  can bind to tubular cell

receptors. As a result, it also triggers the death receptor pathway of apoptosis [34]. Also other

427 studies experienced an elevated IL-6 in seriously ill patients with COVID-19. They observed an

428 increased IL-6 levels in deceased patient than to survivors [35]. The lethal role of IL-6 has been

429 demonstrated in different models [36,37]. Therefore, we can assume that these cytokines may

430 participate to AKI in COVID-19 patients.

We found that COVID-19 patients also generally exhibited kidney disorder with elevated levels
of serum creatinine, BUN followed by proteinuria & hematuria. The occurrence of kidney
disorder in COVID-19 patients might be explained because of the following reasons. The SARSCoV-2 uses angiotensin-converting enzyme 2(ACE2) as a cell entry receptor [38]. This receptor

expressed in a huge amount in the small intestine, testis, kidneys, heart, thyroid, and adipose

tissue [39]. Also, this receptor expressed with a much-elevated level in kidney than that in the

437 lung [8]. Therefore, it is likely that SARS-CoV-2 can also attack kidney epithelial cells in

438 addition to attacking lung epithelial cells [40]. This finding was supported by a recent histology

439 report of renal tissues from autopsies and found acute renal tubular damage in six COVID-19

440	cases [9]. (ii) kidney disorder with other organ can enhance the inflammation process in which
441	injury and death of renal tubular epithelial cells occurred [41,42].

442

443	Limitation: This study has some limitations. The number of patients with AKI was small. Of
444	the included studies a large majority are from China and the findings of this analysis may not be
445	applicable to other part of the world. Clinical data of patient after release from hospital was
446	absent, so we could not evaluate COVID-19 effects on long-term impact on health. More studies
447	are needed to better investigate the risk of AKI and mortality in COVID-19 patients.
448	
449	Conclusion
450	Based on the available limited published data, severe AKI in patients with COVID-19 is a
451	threatening clinical predictor and is associated with high mortality. Further studies are needed to
452	understand the factors associated with worse outcomes among COVID-19 patients with AKI.
453	Understanding those factors may guide care providers in making more informed dialysis
454	eligibility decisions under conditions where resources are extremely limited.
455	
456	Abbreviations
457	AKI: acute kidney injury ; COVID-19: Corona Virus Disease 2019; PRISMA: Preferred
458	Reporting Items for Systematic Reviews and Meta-Analyses; MODS: Multiple Organ
459	Dysfunction Syndromes; ARDS: Acute Respiratory Distress Syndrome; BUN: Blood Urea
460	Nitrogen; eGFR: Estimated Glomerular Filtration Rate.
461	

## 463 **Declarations**

- 464 Ethics approval and consent to participate
- 465 Not applicable
- 466 **Consent for publication**
- 467 Not applicable.
- 468 Availability of data and materials
- 469 Not applicable.
- 470 **Competing interests**
- 471 The authors declare that they have no competing interests.
- 472 Funding
- 473 None
- 474 Authors' contributions
- 475 Conceptualization: MSS and RJ. Data curation: RJ. Investigation: MSS and RJ. Supervision and
- 476 visualization: MSS. Writing original draft preparation: MSS and RJ. Writing Review &
- 477 Editing: MSS and RJ. All authors have read and approved the final manuscript.

478

- 479 Acknowledgments
- 480 Not applicable
- 481 Authors' information
- 482 Not applicable.

- 484
- 485

# 486 **References**

- 487 1.Worldometers. COVID-19 Coronavirus Pandemic. Available from:
- 488 https://www.worldometers.info/coronavirus/ [Accessed 8 June 2023].
- 489
- 490 2.Moher D, Liberati A, Tetzla J, Altman DG 02009) Preferred reporting items for systematic
- 491 reviews and meta-analyses: the PRISMA statement. BMJ 339:b2535.
- 492
- 493 3. MedCalc Software. MedCalc statistical software version 16.4. 3.[computer software].

494

- 495 4. Lim JH, Park SH, Jeon Y, Cho JH, Jung HY, Choi JY, Kim CD, Lee YH, Seo H, Lee J, Kwon
- 496 KT. Fatal Outcomes of COVID-19 in Patients with Severe Acute Kidney Injury. Journal of

497 Clinical Medicine. 2020 Jun;9(6):1718.

- 498
- 499 5. Shao L, Li X, Zhou Y, Yu Y, Liu Y, Liu M, Zhang R, Zhang H, Wang X, Zhou F. Novel
- 500 Insights Into Illness Progression and Risk Profiles for Mortality in Non-survivors of COVID-19.

501 Frontiers in Medicine. 2020 May 22; 7:246.

502

- 503 6.Cheng Y, Luo R, Wang K, Zhang M, Wang Z, Dong L, Li J, Yao Y, Ge S, Xu G. Kidney
- disease is associated with in-hospital death of patients with COVID-19. Kidney international.

505 2020 Mar 20.

507	7. Wang D.	Yin Y.	Hu C, Liu X	Zhang X.	Zhou S.	Jian M. Xu H	H. Prowle J.	Hu B. Li Y.	Clinical
507	,, ,, ang 2,	<b></b> ,	114 0, 114 11	, <b>Dirang</b> 11,	Linea o,	01411 111, 114 I	<b>1</b> , <b>1 1 0 0 10 0 0</b>	116 2, 21 1.	Chinean

- 508 course and outcome of 107 patients infected with the novel coronavirus, SARS-CoV-2,
- discharged from two hospitals in Wuhan, China. Critical Care. 2020 Dec; 24:1-9.
- 510
- 511 8. Li Z, Wu M, Yao J, Guo J, Liao X, Song S, Li J, Duan G, Zhou Y, Wu X, Zhou Z. Caution on
- 512 kidney dysfunctions of COVID-19 patients.
- 513
- 514 9. Diao B, Feng Z, Wang C, Wang H, Liu L, Wang C, Wang R, Liu Y, Liu Y, Wang G, Yuan Z.
- 515 Human kidney is a target for novel severe acute respiratory syndrome coronavirus 2 (SARS-
- 516 CoV-2) infection. MedRxiv. 2020 Jan 1.
- 517
- 518 10. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, Ren R, Leung KS, Lau EH, Wong JY, Xing
- 519 X. Early transmission dynamics in Wuhan, China, of novel coronavirus–infected pneumonia.
- 520 New England Journal of Medicine. 2020 Jan 29.
- 521
- 522 11. Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J, Xing F, Liu J, Yip CC, Poon RW, Tsoi
- 523 HW. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating
- 524 person-to-person transmission: a study of a family cluster. The Lancet. 2020 Feb
- 525 15;395(10223):514-23.
- 526
- 527 12. Yang Y, Lu Q, Liu M, Wang Y, Zhang A, Jalali N, Dean N, Longini I, Halloran ME, Xu B,
- 528 Zhang X. Epidemiological and clinical features of the 2019 novel coronavirus outbreak in China.
- 529 MedRxiv. 2020 Jan 1.

5	3	0
-	-	~

- 531 13.Shimada M. BMJ Best practice, Assessment of elevated creatinine. Available from:
- https://bestpractice.bmj.com/topics/en-gb/935 [Accessed 13 June 2020].

533

- 14. Pagana KD, Pagana TJ. Mosby's Manual of Diagnostic and Laboratory Tests-E-Book.
- 535 Elsevier Health Sciences; 2017 Oct 8.

536

- 537 15. American Association for Clinical Chemistry (AACC), Estimated Glomerular Filtration Rate
- 538 (eGFR). Available from: https://labtestsonline.org/tests/estimated-glomerular-filtration-rate-
- 539 egfr). [Accessed 13 June 2020].

540

- 16.Huang MJ, Wei RB, Su TY, Wang Y, Li QP, Yang X, Lv XM, Chen XM. Impact of acute
- kidney injury on coagulation in adult minimal change nephropathy. Medicine. 2016 Nov;95(46).
- 544 17. Khatri M. Proteinuria. WebMD LLC, [Online]. Available: https://www.webmd.com/a-to-z545 guides/qa/what-is-proteinuria. [Accessed 13 June 2020]. 2015.

546

- 18. Lerma EV. Proteinuria. WebMD LLC, [Online]. Available: http://emedicine. medscape.
- 548 com/article/238158-overview.[Accessed 29 August 2016]. 2015.

- 19. Bignall ONR, 2nd, Dixon BP. Management of Hematuria in Children. Curr Treat Options
  Pediatr. 2018;4(3):333-49.
- 552

553	20. Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and
554	consequences of cytokine storm and immunopathology. Semin Immunopathol. 2017;39(5):529-
555	39.
556	
557	21. Conti P, Ronconi G, Caraffa AL, Gallenga CE, Ross R, Frydas I, Kritas SK. Induction of
558	pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-
559	19 or SARS-CoV-2): anti-inflammatory strategies. J Biol Regul Homeost Agents. 2020 Mar
560	14;34(2):1.
561	
562	22. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z.
563	Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The lancet.
564	2020 Feb 15;395(10223):497-506.
565	
566	23. Yang Y, Shen C, Li J, Yuan J, Yang M, Wang F, Li G, Li Y, Xing L, Peng L, Wei J.
567	Exuberant elevation of IP-10, MCP-3 and IL-1ra during SARS-CoV-2 infection is associated
568	with disease severity and fatal outcome. MedRxiv. 2020 Jan 1.
569	
570	24. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, Yu T.
571	Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in
572	Wuhan, China: a descriptive study. The Lancet. 2020 Feb 15;395(10223):507-13.
573	

574	25. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-
575	19 based on an analysis of data of 150 patients from Wuhan, China. Intensive care medicine.
576	2020 May;46(5):846-8.
577	26. Jin JM, Bai P, He W, Wu F, Liu XF, Han DM, Liu S, Yang JK. Gender differences in
578	patients with COVID-19: Focus on severity and mortality. Frontiers in Public Health. 2020 Apr
579	29;8:152.
580	
581	27. Yang JK, Feng Y, Yuan MY, Yuan SY, Fu HJ, Wu BY, et al. Plasma glucose levels and
582	diabetes are independent predictors for mortality and morbidity in patients with SARS. Diabet
583	Med. 2006;23(6):623-8.
584	
585	28. Yang J-K, Lin S-S, Ji X-J, Guo L-M. Binding of SARS coronavirus to its receptor damages
586	islets and causes acute diabetes. Acta Diabetol. 2010;47(3):193-9.
587	29. Patel SK, Velkoska E, Burrell LM. Emerging markers in cardiovascular disease: where does
588	angiotensin-converting enzyme 2 fit in? Clin Exp Pharmacol Physiol. 2013;40(8):551-9.
589	
590	30.Betjes MG. Immune cell dysfunction and inflammation in end-stage renal disease. Nature
591	Reviews Nephrology. 2013 May;9(5):255.
592	
593	31.Cohen-Hagai K, Rozenberg I, Korzets ZE, Zitman-Gal T, Einbinder Y, Benchetrit S. Upper
594	respiratory tract infection among Dialysis patients. Isr. Med. Assoc. J. 2016 Sep 1;18:557-60.
595	

- 596 32.Sibbel S, Sato R, Hunt A, Turenne W, Brunelli SM. The clinical and economic burden of
- 597 pneumonia in patients enrolled in Medicare receiving dialysis: a retrospective, observational
- cohort study. BMC nephrology. 2016 Dec 1;17(1):199.
- 599
- 33.Gabarre P, Dumas G, Dupont T, Darmon M, Azoulay E, Zafrani L. Acute kidney injury in
- critically ill patients with COVID-19. Intensive Care Medicine. 2020 Jun 12:1-0.

602

- 603 34.Cunningham PN, Dyanov HM, Park P, Wang J, Newell KA, Quigg RJ. Acute renal failure in
- endotoxemia is caused by TNF acting directly on TNF receptor-1 in kidney. The Journal of
- 605 Immunology. 2002 Jun 1;168(11):5817-23.

606

- 607 35.Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L. Clinical
- 608 course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a
- retrospective cohort study. The lancet. 2020 Mar 11.

610

36.Su H, Lei CT, Zhang C. Interleukin-6 signaling pathway and its role in kidney disease: an
update. Frontiers in immunology. 2017 Apr 21; 8:405.

- 614 37.Nechemia-Arbely Y, Barkan D, Pizov G, Shriki A, Rose-John S, Galun E, Axelrod JH. IL-
- 615 6/IL-6R axis plays a critical role in acute kidney injury. Journal of the American Society of
- 616 Nephrology. 2008 Jun 1;19(6):1106-15.
- 617

- 618 38.Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, Si HR, Zhu Y, Li B, Huang CL,
- 619 Chen HD. A pneumonia outbreak associated with a new coronavirus of probable bat origin.
- 620 nature. 2020 Mar;579(7798):270-3.
- 621
- 39.Li MY, Li L, Zhang Y, Wang XS. Expression of the SARS-CoV-2 cell receptor gene ACE2
- 623 in a wide variety of human tissues. Infectious diseases of poverty. 2020 Dec;9:1-7.

624

- 40. Yeung ML, Yao Y, Jia L, Chan JF, Chan KH, Cheung KF, Chen H, Poon VK, Tsang AK, To
- 626 KK, Yiu MK. MERS coronavirus induces apoptosis in kidney and lung by upregulating Smad7
- and FGF2. Nature microbiology. 2016 Feb 22;1(3):1-8.

628

- 41.Faubel S, Edelstein CL. Mechanisms and mediators of lung injury after acute kidney injury.
- 630 Nature Reviews Nephrology. 2016 Jan;12(1):48.

631

- 42.Wang H, Ma S. The cytokine storm and factors determining the sequence and severity of
- organ dysfunction in multiple organ dysfunction syndrome. The American journal of emergency
- 634 medicine. 2008 Jul 1;26(6):711-5.
- 635
- 43.Ronco C, Reis T, Husain-Syed F. Management of acute kidney injury in patients with
- 637 COVID-19. The Lancet Respiratory Medicine. 2020 May 14.

- 639 44.Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, Mehra MR,
- 640 Schuepbach RA, Ruschitzka F, Moch H. Endothelial cell infection and endotheliitis in COVID-
- 641 19. The Lancet. 2020 May 2;395(10234):1417-8.
- 642
- 45.Su H, Yang M, Wan C, Yi LX, Tang F, Zhu HY, Yi F, Yang HC, Fogo AB, Nie X, Zhang C.
- Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China.
- 645 Kidney international. 2020 Apr 9.
- 646
- 46.Larsen CP, Bourne TD, Wilson JD, Saqqa O, Moh'd A S. Collapsing Glomerulopathy in a
- Patient With COVID-19. Kidney international reports. 2020 Jun 1;5(6):935-9.
- 649
- 47.Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L. Clinical
- course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a
- retrospective cohort study. The lancet. 2020 Mar 11.
- 653
- 48.Ronco C, Reis T. Kidney involvement in COVID-19 and rationale for extracorporeal
- therapies. Nature Reviews Nephrology. 2020 Apr 9:1-3.